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Abstract 
Platelet serotonin (5-HT) can  be used as a limited, peripheral model for the central 5-HT 
synaptosomes. Altered platelet 5-HT concentrations have been associated with psychiatric 
disorders like depression and schizophrenia. The aim of the present study was to compare 
platelet 5-HT concentrations during long, medium and short period of natural daylight 
exposure in a large number of medication-free male and female schizophrenic and depressed 
patients and sex-matched healthy controls. Platelet 5-HT concentration was determined 
spectrofluorimetrically in 240 (97 female, 143 male) schizophrenic and 258 (153 female, 105 
male) nonpsychotic, nonsuicidal depressed medication-free patients and 328 (149 women, 
179 men) healthy subjects during periods with short (<12), long (>12) and medium (average 
12) hours of the natural daylight.  Platelet 5-HT concentration was significantly lower in 
women compared to men in all groups. Healthy male subjects had significantly higher 
(p=0.011) platelet 5-HT concentrations during long compared to medium period. There were 
no significant differences (p>0.05) in platelet 5-HT concentration between different periods in 
healthy women. The significant increase in platelet 5-HT values were found in female 
(p=0.01) and male (p=0.029) depressed patients during long compared to short period. There 
were no significant associations between platelet 5-HT concentrations and different periods in 
both male and female schizophrenic patients. The results indicate the sex-related differences 
in the serotonergic system. The alterations of platelet 5-HT concentrations, observed across 
period with different durations of daylight exposure, point to a direct or indirect effect of light 
on peripheral 5-HT system that could be related to different sensitivity of the pineal gland to 
light and/or melatonin influence on 5-HT metabolism. 
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         Introduction 
 
         Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter implicated in a variety of 
somatic functions that are disturbed in psychiatric disorders like depression and schizophrenia 
[1]. Biological factors predisposing a person to a major depression point to alterations in 
presynaptic and postsynaptic 5-HT activity in the brain and their relationship with the 
neuroendocrine system [2] . Alterations in the serotonergic system have also been related to 
specific symptoms and treatment of schizophrenia, since novel antipsychotic agents, which 
are 5-HT2A receptors antagonists, provide better treatment response than classical 
neuroleptics [3].  
 
         Serotonin is synthesized from the amino acid tryptophan, an essential amino acid found 
in the human diet which contains an indole ring. Tryptophan, due to its indole structure, is 
capable of absorbing the light energy [4]. Biosynthesis of 5-HT in the human body takes place 
in the nervous system (serotonergic neurons, spinal cord), peripheral organs (gastrointestinal 
tract, lungs, liver, ovaries), glands (thyroid, pancreas, pineal) [5-7] and some neoplastic 
tissues (carcinoid tumors and phaeocromocytoma) [8-9]. In the pineal gland, with very 
pronounced 5-HT synthesis rate [10], 5-HT is the precursor of the neurohormone melatonin 
[11-12]. Melatonin regulates biological rhythms and levels of biomolecules that exert various 
peripheral actions, thus affecting many critical processes [13]. Various studies have shown 
altered melatonin secretion in depression [14-19], seasonal affective disorder (SAD) [20-21], 
schizophrenia [22-26], panic disorder [27], obsessive-compulsive disorder [17,28]  and 
Alzheimer’s disease [29], suggesting an interaction of melatonin with the central 
neurotransmitter systems.  
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         Goergen et al (2002) have shown that light-controlled rhythm could be the primary 
regulator of neuronal proliferation and that previously demonstrated hormonal and activity-
driven influences over neurogenesis may be the secondary events in a complex circardian 
control pathway [30]. Recently, it has been shown  that brain 5-HT concentration correlates 
positively with the hours of sun exposure per day in a healthy male volunteers [31]. Since 5-
HT does not cross the blood-brain barrier, direct studies on brain 5-HT metabolism are still 
very limited. Blood platelets have been used in neurobiological studies as a limited, peripheral 
model for serotonergic nerve endings in the brain. Uptake, storage, and release of 5-HT into 
platelets and the kinetic and pharmacological characteristics of platelet receptors resemble the 
corresponding processes and receptors in the central serotonergic neurons [32-33]. Previous 
studies have shown unchanged [34a,b] or decreased [35] platelet 5-HT concentration in 
depressed patients. In schizophrenic patients platelet 5-HT concentration was increased [36-38] 
or unaltered [39-40]. There are several studies reporting altered platelet 5-HT uptake depending 
on the season in depressed [41-42] and schizophrenic [43] patients and indicating that in 
schizophrenic patients platelet 5-HT levels depend on the season of birth [44]. These results 
suggest that platelet 5-HT concentrations could depend on duration of natural daylight.   
 
         Since there are no data related to the effects of natural daylight on platelet 5-HT levels, the 
aim of the present study was a) to determine platelet 5-HT concentration in a large number of 
medication-free male and female schizophrenic and depressive patients and in sex-matched 
healthy controls b) to compare platelet 5-HT concentrations in all groups during long, medium 
and short period  with different duration of natural daylight. 
  
         Materials and Methods 
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         The population studied comprised of 97 nonsuicidal female (mean age 40.6 ± 10.8 
years, range 36-59 years) and 143 male (mean age 39.2 ± 10.5 years, range 29-55 years)  
schizophrenic patients and 153 female nonpsychotic, nonsuicidal (mean age 43.6 ± 10.2 
years, range 37-59 years) and 105 male (mean age 44.2 ± 11.8 years, range 35-60 years) 
depressed patients. The clinical diagnosis of schizophrenia and major depression was made by 
a team of psychiatrists during a comprehensive screening evaluation, using the structured 
clinical interview (SCID) [45] based on DSM-IV criteria [46]. In schizophrenic patients mean 
score on Brief Psychiatry Rating Scale was 56.5 ± 8.9. The severity of depression was 
evaluated using on 17-item Hamilton Depression Rating Scale (HAM-D) [47]. In depressed 
patients mean HAMD was 25.4 ± 3.3. Before blood sampling, patients were not treated with 
any neuroleptic or antidepressant drugs for at least 7 days. The study was performed during a 
2 year period. Clinical ratings and biochemical measures were made blindly to each other. 
The control group consisted of medication free 149 healthy women (mean age 39.5 ± 7.7; years, 
range 25-57 years) and 179 men (mean age 35.4 ± 8.7; years, range  24-54 years)  with no 
personal or family history of psychopathology. The study was approved by Local Ethics 
Committee and all participants gave their informed consent.  
 
         Blood samples were taken from patients and healthy controls in three periods of the year 
with different duration of natural daylight:1) long period with average 16 hours (from 21st May 
to 21st July), 2) short period with average 8 hours (from 21st November to 21st January) and 3) 
medium period with average 12 hours (from 21st February to 21st April 21st  and from 23thAugust 
to 23th September) of natural daylight. At the time of blood collection, all female subjects were in 
the same day of  menstrual cycle. Blood (4 ml) was drawn from cubital vein at 8:00 h in a plastic 
syringe with 1 ml of acid citrate dextrose (ACD) anticoagulant. Platelet-rich-plasma (PRP) was 
obtained by centrifugation (935 x g) for 70 s at room temperature. Platelets were sedimented by 
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further centrifugation of PRP at 10,000 x g for 5 min. The pellet was washed with saline and 
centrifuged again. Platelet 5-HT concentrations were determined by spectrofluorimetric method 
[36]. Briefly, platelets were destroyed by sonication (20 kHz, amplitude 8 x 10-3 mm for 30 sec). 
Specimens of standard, blank (water) and platelet sonicates were analyzed in duplicate. All 
samples were deproteinized with 1 ml of 10% ZnSO4 and 0.5 ml of 1 N NaOH. For the 
preparation of fluorophore, 0.2 ml of L-cysteine (0.1%) and 1.2 ml of orthophthalaldehyde 
(0.05%) were added to deproteinized samples. The measurement of the 5-HT fluorescence was 
performed on a Varian Cary Eclipse spectrofluorimeter. Platelet protein was determined by the 
method of  Lowry et al., [48]. All data are presented as mean ± SD. The differences  between 
groups were assessed by Kruskal Wallis one way analysis of variance (ANOVA) on ranks, 
followed by Mann Whitney t-test for comparison of the two groups. The statistical package used  
was SigmaStat 3.1. 
  
         Results 
 
         The sex-related difference in platelet 5-HT concentrations was observed (Table 1) in 
depressed and schizophrenic patients and healthy controls. Healthy men and male patients 
with depression or schizophrenia had significantly (p<0.05) higher platelet 5-HT 
concentrations than healthy women and female depressed or schizophrenic patients, 
respectively. 
 
 
         In male depressed patients and healthy men significant (H=12.01; df=5; p<0.035; 
Kruskal-Wallis ANOVA) differences in platelet 5-HT concentrations were found across 
different periods (Fig 1). Platelet 5-HT concentrations were significantly increased (p=0.029, 
Mann Whitney test) in male depressed patients during long period compared to platelet 5-HT 
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values in those patients during short period. Similarly, healthy male subjects had significantly 
higher (p=0.011) platelet 5-HT concentrations during long period compared to medium 
period. 
 
         Figure 2. shows significant differences (H=22,8; df=5; p<0.001; Kruskal-Wallis 
ANOVA) in platelet 5-HT concentrations during long, short or medium periods in female 
depressed patients and sex matched healthy controls. Depressed female patients had 
significantly (p=0.025 and p<0.001) lower platelet 5-HT concentrations during medium and 
short period than  healthy female controls in the corresponding periods. Platelet 5-HT values 
in patients during long period were significantly higher than platelet 5-HT levels in patients 
during short (p=0.01) and medium (p<0.001) periods. There were no significant (p>0.05) 
differences in platelet 5-HT concentrations during different periods in healthy female control 
subjects (Fig 2). 
 
        Platelet 5-HT concentrations in male and female schizophrenic patients and male and 
female healthy controls during periods with different duration of natural daylight are shown in 
Table 2. A significant (p<0.01) increase in platelet 5-HT concentrations was observed in both 
male and female patients  compared to sex-matched healthy controls, independent of the long, 
medium or short period. 
 
        Discussion 
 
         In the present study, we have confirmed and extended our previous results showing 
different platelet 5-HT concentrations in male and female depressed [34 a,b] and 
schizophrenic patients [44] and healthy controls [34a,b, 44]. The observed sex-related 
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difference in platelet 5-HT concentration is in line with the findings that brain 5-HT synthesis 
rate is lower in healthy women than in healthy men [49]. Further support is the sex-related  
difference obtained in healthy volunteers in response to m-chlorophenyl-piperazine (mCPP) 
challenge test, a measure of serotonergic function [50]. Taken together, these results suggest 
that sex-related differences in 5-HT system could be the reason for higher incidence of 
depression in women compared to men [51]. 
 
         Our result, indicating the sex-related difference in platelet 5-HT concentration in 
depressed patients, is in line with the finding of the sex-dependent alteration in 5-HT uptake 
into platelets. Different kinetic characteristics of platelet [14C]-5-HT uptake and [3H]-
paroxetine binding were determined in male and female depressed patients [52]. In addition, 
the sex-related difference in diencephalon 5-HT transporter availability was discovered in 
depression, explaining why women respond better to treatment with selective serotonin 
reuptake inhibitor (SSRI) antidepressants compared to men [53].  These results illustrate 
important sex-related differences associated with human 5-HT system dysfunction present in 
depression and characterize the pathophysiology of the illness itself. 
 
         Furthermore, our findings support the opinion of other authors [54-60] who emphasize 
that different approaches to treatment of disorders heavily associated with 5-HT system 
(depression, schizophrenia, anorexia nervosa, panic disorder, personality disorders, 
posttraumatic stress disorder, irritable bowel syndrome, Alzheimer disease) should be 
exercised depending on the sex of the patient.  
 
         The main finding in the present study is the association between platelet 5-HT 
concentrations and the amount of the natural daylight  in healthy male subjects and male and 
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female depressed patients. Our results, showing that healthy male subjects have higher 
platelet 5-HT values during period with highest duration of natural daylight (long period) 
compared to platelet 5-HT values during other periods, are in agreement with the observed 
increase of 5-HT levels and 5-HT turnover in the brain on bright days in medication-free 
healthy male volunteers [31] and with the increased platelet 5-HT uptake in healthy subjects in 
summer compared to autumn [61]. At present, we are unable to explain the lack of the similar 
finding in the case of healthy female subjects. The sex-related difference in platelet 5-HT 
content could be linked to sex difference in the sensitivity of the pineal gland to light and/or to 
difference in melatonin influence on 5-HT metabolism and subsequent neurotransmission [62-
65]. 
 
         The chronobiological mechanisms controlling the release of melatonin, which plays a 
significant role in the control of the central and the peripheral metabolism of 5-HT, could 
account for the observed differences in platelet 5-HT content depending on different duration 
of exposure to natural daylight. Our results, showing lower platelet 5-HT levels in depressed 
patients compared to healthy control subjects within the same period, could be a direct 
consequence of the altered melatonin production and/or disruption of melatonin's biological 
functions present in depressive disorders. Although in our study we did not measure the 
plasma melatonin levels, literature data shows increased secretion of melatonin in depressed 
patients [14-18], suggesting an interaction of melatonin with the 5-HT system.  
 
         In the present study we have not observed the association between platelet 5-HT 
concentration and duration of daylight exposure in medication-free schizophrenic patients. 
This finding is in agreement with our previous results showing no seasonal influence on 
platelet 5-HT concentrations in schizophrenic patients [38]. The literature data on the 
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circadian rhythm and melatonin secretion in schizophrenic patients is scarce and often 
contradictory. To our knowledge, there is no data regarding the melatonin secretion in 
schizophrenic patients depending on different duration of natural daylight. Several studies 
[22,25,26,66] indicate diminution of melatonin secretion in schizophrenia, which argues in 
support of the overall increase in the platelet 5-HT levels observed in patients compared to 
controls. The effect of decreased melatonin production, resulting in premature calcification 
and enlargement of the pineal gland, has been correlated with the frontal lobe atrophy 
observed in schizophrenic patients and consequently implicated in the pathogenesis of 
schizophrenia [24,67,68].  
 
         Our results, showing an increase in the platelet 5-HT content during long and a decrease 
during short period, point to a direct or an indirect effect of light on the central and the 
peripheral 5-HT system. The pineal gland has an essential role in the regulation of the 
circadian rhythm and responds to light by sending the information via a retinohypothalamic 
tract to suprachiasmatic nuclei, densely innervated by 5-HT neurons from the mid-brain raphe 
complex [69-71], resulting in the secretion of melatonin. Melatonin, following its synthesis 
from the precusor 5-HT, acts as an important biochemical mediator, controlling the neural 
mechanisms responsible for receiving and transmitting the light stimulus. Its synthesis and 
secretion is regulated by the circadian clock in the hypothalamus which is synchronized with 
the light/dark period [72]. It has been shown that melatonin blocks the circadian rhythm of 5-
HT synthesis in the pineal gland, inhibits the pineal 5-HT uptake and alters the hypothalamic 
5-HT release [73a,b,74]. Another study by Monnet (2002) provides a direct evidence that 
melatonin affects the circadian rhythm of 5-HT neurotransmission in the hippocampus, a 
major target of serotoninergic antidepressants, suggesting the involvement of at least two 
different mechanisms by which melatonin regulates the spontaneous efflux of 5-HT during 
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the dark phase and the evoked release of 5-HT during the light phase in the hippocampus [72]. 
The mechanism behind the pattern of melatonin secretion during the dark cycle is controlled 
by the rate-limiting enzyme in melatonin synthesis - serotonin N-acetyltransferase, which is 
low during daylight and peaks during the dark phase [76]. Additionally, it has been shown 
that melatonin acts as a 5-HT2c receptor antagonist [77].  
 
         Recently, melatonin has been regarded as a cytoskeletal modulator, actively 
participating during axogenesis and neurite formation [78]. Some neurodegenerative and 
psychiatric diseases such as schizophrenia, Alzheimer’s and Parkinson’s disease have been 
associated with abnormal cytoskeleton organization of neurons that loose synaptic 
connectivity leading to impaired neurotransmission. With respect to that, increased melatonin 
secretion would act in the context of cytoskelatal disorganisation and impaired neurite 
formation, providing for disease progression [78-79]. In addition, due to its cytoskeleton-
modulating features, melatonin has been considered as a possible therapeutic agent for mental 
disorders [78].  
 
         The limitation of the present study is that we did not compare platelet 5-HT 
concentrations with the daylight hours in a particular samples. Although some authors [31] 
suggest that 5-HT levels are directly implicated with the hours of sun exposure per day, we 
did not measure the intensity of the natural daylight.  
 
         Conclusion 
 
         The results have shown that platelet 5-HT concentration is sex dependent, being 
constantly lower in female subjects compared to male regardless of the mental health status. 
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The duration of natural daylight exposure is associated with platelet 5-HT concentration in 
healthy male subjects and depressed male and female patients but not in healthy female 
subjects and schizophrenic patients. The magnitute of described effects of daylight on 
peripheral serotonin concentration was small but significant statistically, however taken that 
even the most subtle changes in the brain chemistry can have profound effects on the well 
being of healthy persons and psychiatric patients, these effects should not be overlooked. 
Overall, the results of the present study suggest that different platelet 5-HT concentrations, 
observed in depressed patients across different photoperiods, could be linked to differences in 
the sensitivity of the pineal gland to light or to diverse effects of melatonin on the 5-HT 
metabolism. More detailed investigations of the relationship between the light exposure, 
melatonin and the 5-HT system would help in understanding the pathophysiology of 
depression and schizophrenia.  
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Figure legends 
Fig 1. Platelet 5-HT concentrations in healthy men and depressed men patients during 
periods with different duration of natural daylight. Bars represent mean ± S.D. with number of 
subjects in parentheses.  
*p=0.029 vs. depressed patients during short period;  
** p=0.011 vs. healthy men during medium period  (Kruskal-Wallis ANOVA, followed by 
Mann-Whitney test) 
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Fig 2.  Platelet 5-HT concentrations in healthy women and depressed women during  periods 
with different duration of natural daylight. Bars represent mean ± S.D. with number of 
subjects in parentheses.  
*p=0.025 vs. healthy women during short period; 
** p<0.001 vs. healthy women during medium period 
# p=0.01 vs. depressed patients during short period  
## p<0.001  vs. depressed  women during medium period (Kruskal-Wallis ANOVA, followed 
by Mann-Whitney test)  
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Table 1. Platelet 5-HT concentrations in male and female healthy controls, depressed and 
schizophrenic patients. Results are expressed as mean ± SD. Number of subjects is given in 
parenthesis. 
 
 
 
 
 
Table 2. Platelet 5-HT concentrations in male and female healthy controls and schizophrenic 
patients during periods with different duration of natural daylight. Results are expressed as 
mean ± SD. Number of subjects is given in parenthesis.  
*p<0.01 vs. sex matched healthy controls in corresponding photoperiod (Kruskal-Wallis 
ANOVA, followed by Mann-Whitney test). 
 
 
 Platelet 5-HT   (nmol/ mg proteins) 
 Period 
 Long Medium Short 
Kruskal-Wallis 
ANOVA 
df =5  
 H                p 
Men:  
Healthy controls 1.38 ± 0.37 
(26) 
1.19 ± 0.31 
(117) 
1.21 ± 0.26 
(36) 
Schizophrenic patients 1.46 ± 0.38* 
(27) 
1.51 ± 0.56* 
(79) 
1.64 ± 0.55* 
(37) 
 
 
   42.7        <0.001 
 
Women:  
Healthy controls 1.11 ± 0.33 
(41) 
1.18 ± 0.25 
(64) 
1.17 ± 0.28 
(44) 
Schizophrenic patients 1.45 ± 0.45* 
(24) 
1.36 ± 0.51* 
(57) 
1.45 ± 0.44* 
(27) 
 
 
  22.6         <0.001 
 
 
 Platelet 5-HT 
(nmol/ mg proteins) 
                ANOVA 
         F            df              P 
Healthy controls: 
-men (179) 
-women (149) 
 
1.22  ±  0.31 
1.15  ±  0.28 
 
3.945       1,326        0.048 
Depressed patients: 
-men (105) 
-women (153) 
 
1.21  ±  0.32 
1.12  ±  0.35 
 
4.041       1,256       0.045 
Schizophrenic patients: 
-men (143) 
-women (97) 
 
1.54  ±  0.53 
1.39  ±  0.50 
 
4.935       1,338       0.027 
